Fundraising Fox
/Companies
Sign in

Vivet Therapeutics

Paris, FR · Founded 2016 · 17 employees on LinkedIn · 9 known investors

Find your way into Vivet Therapeutics

Sign up to find every way you can get introduced to Vivet Therapeutics

  • Your email: who you already know at Vivet Therapeutics, and who your contacts know
  • 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Vivet Therapeutics team
  • Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Sign up with GoogleAlready have an account? Log in

Vivet Therapeutics is a clinical-stage biotechnology company developing recombinant adeno-associated virus (rAAV) gene therapies for rare, inherited metabolic diseases, including Wilson's Disease and cerebrotendinous xanthomatosis. Its pipeline is built on technologies licensed from FIMA at the University of Navarra in Spain.

BiotechHealthtech

Investors · 9

Kurma Partners✓ confirmed by Vivet TherapeuticsParis · $162K – $10.8M

How we know: Kurma Partners's portfolio page · the company's own site · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us

Novartis Venture Fund✓ confirmed by Vivet TherapeuticsBasel · $5M – $25M

How we know: Novartis Venture Fund's portfolio page · the company's own site · funding news · Not right? Tell us

Roche Venture Fund✓ confirmed by Vivet TherapeuticsBasel · $648K – $3.2M

How we know: Roche Venture Fund's portfolio page · the company's own site · open dataset · 5k.vc investor directory · Not right? Tell us

Ysios Capital✓ confirmed by Vivet TherapeuticsBarcelona · $5.4M – $21.6M

How we know: Ysios Capital's portfolio page · the company's own site · the VCSheet dataset · Not right? Tell us

Columbus Venture Partners✓ confirmed by Vivet TherapeuticsValenciavia Jose Mesa · inferred

How we know: the company's own site · the VCSheet dataset · Not right? Tell us

Eurazeo✓ confirmed by Vivet TherapeuticsParis

How we know: the company's own site · Not right? Tell us

Pfizer Venture Investmentslisted by Pfizer Venture Investments$5M – $20M

How we know: Pfizer Venture Investments's portfolio page · Not right? Tell us

Also in the syndicate · 1

Pfizer

Funding

SEC filings, press & company announcements

Source: company announcements and press reports — follow each round's link for the claim.

Related companies · 7

ClementiaIpsen is a biopharmaceutical group that publishes financial, legal, and non-financial reporting for shareholders, investors, and the public through documents such as its Universal Registration Document. The page is the investor reports and accounts section of the company's corporate site.
GatsbyGatsby is an event management platform that sends invitations from partners' actual email accounts and provides customizable registration pages with guest profiles and adaptive forms.
JefferiesJefferies is a financial services firm offering investment banking, wealth management, and related capital markets services. The captured page is a multilingual fraud-alert notice warning that impersonators are misusing the Jefferies name to solicit fake investments and jobs.
IO BiotechIOBiotech appears to be a biotech company focused on oncology, with a founder who has extensive experience in cancer drug development and clinical advancement from roles at Roche, Eli Lilly, and leading academic cancer centers.
Kodiak SciencesKodiak Sciences develops biopharmaceutical therapies for chronic ophthalmic diseases, with a focus on patient outcomes and stakeholder impact in the healthcare system.
PrecisionLifePrecisionLife uses advanced AI and analytics to identify the biological mechanisms underlying complex chronic diseases, enabling earlier diagnosis and more personalized treatment selection. The company develops diagnostic tests, clinical tools, and insights for pharmaceutical and healthcare partners to improve disease understanding and patient outcomes across multiple therapeutic areas.
MedscapeMedscape is an online platform providing medical news, clinical information, and continuing education resources to physicians and healthcare professionals globally. The platform offers CME courses, drug and disease information, and patient education across multiple specialties.

Companies working in the same space as Vivet Therapeutics.

In the news

Investors - Vivet Therapeuticsvivet-therapeutics.com · Jan 2022Homepage - Vivet Therapeuticsvivet-therapeutics.com · Sep 2019Vivet Therapeutics Raises €37.5 Million in Series A Financing Round to Advance Novel Gene Therapies for Treating Inherited Metabolic Diseasesprnewswire.com · May 2017Vivet Therapeutics raises €37.5 million in Series A financing round - Vivet Therapeuticsvivet-therapeutics.com · Apr 2017

Frequently asked questions

What does Vivet Therapeutics do?
Vivet Therapeutics is a clinical-stage biotechnology company developing recombinant adeno-associated virus (rAAV) gene therapies for rare, inherited metabolic diseases, including Wilson's Disease and cerebrotendinous xanthomatosis. Its pipeline is built on technologies licensed from FIMA at the University of Navarra in Spain.
Who are Vivet Therapeutics's investors?
Vivet Therapeutics's investors include HealthCap, Kurma Partners, Novartis Venture Fund, Roche Venture Fund, Ysios Capital, Columbus Venture Partners, Eurazeo, Pfizer Venture Investments.
Where is Vivet Therapeutics headquartered?
Vivet Therapeutics is headquartered in Paris, FR.